Micromet

Contact
micromet.de
+1240752-1420

Micromet Inc.

6707 Democracy Blvd., Suite 505
20817 Bethesda
USA
+1240752-1420
micromet.de
Contact
Profile Products News
Contact

About Micromet

Read more about Micromet
Facts about Micromet
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Micromet

Product portfolio

Show all

News about Micromet

Micromet

31-Jan-2012 | business & finance

Amgen to Acquire Micromet

All-Cash Transaction Values Micromet at $1.16 Billion

Read news
Micromet

15-Jul-2011 | business & finance

Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen

Maximum deal value of EUR 695 million plus royalties and development cost reimbursement

Read news
Micromet

22-Sep-2010 | research and development

Micromet Initiates Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Micromet, Inc. announced the initiation of a phase 2 trial of the Company’s lead product candidate blinatumomab (MT103) in adult patients with relapsed or ...

Read news
Micromet

16-Jun-2010 | research and development

Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non- Hodgkin's Lymphoma

Micromet, Inc. announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients ...

Read news
Micromet

10-May-2010 | business & finance

Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody

Boehringer Ingelheim and Micromet, Inc. announced that they have entered into a collaboration agreement for the research, development and commercialization ...

Read news
Micromet

11-Dec-2009 | research and development

Phase 2 Study Confirm High Response Rate of Micromet’s Blinatumomab in Patients with Acute Lymphoblastic Leukemia

Micromet, Inc. announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL ...

Read news
Micromet

03-Dec-2009 | business & finance

Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet

Micromet, Inc. announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on ...

Read news
Micromet

10-Nov-2009 | business & finance

Micromet Buys Out MedImmune’s Remaining Rights to Blinatumomab

Micromet, Inc. announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune’s rights to blinatumomab in North America, and to ...

Read news
Show more news about Micromet

Here you will find Micromet Inc.